Abstract presented at EHA2022 describing a study of zanubrutinib in acalabrutinib-intolerant patients
with B-cell malignancies.
Abstract presented at EHA2022 describing preliminary data from a phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies.
The Satellite Symposium at BSH 2022 provided expert insights into treatment options in WM, the emerging role of BTKis in WM, and BTKi-associated toxicities and their management.
The Satellite Symposium at ESH CLL was chaired by Prof Pierre Feugier joined by Prof Federico Pea, Dr Othman Al-Sawaf and Prof Wojciech Jurczak. They discuss managing and treating both treatment naïve (TN) and relapsed/refractory (R/R) CLL patients.
SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
